IL-PROJECT44
11.6.2020 13:02:07 CEST | Business Wire | Press release
project44 , the global leader in advanced visibility for shippers and logistics service providers, today announced the industry’s first Global Preferred Carriers Program . This program evaluates and recognizes — through a monthly published list — less-than-truckload (LTL) and truckload carriers in the project44 network that have demonstrated excellence in performance, consistency, delivery of high-fidelity data and shipment visibility across multiple loads.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200611005018/en/
Through this program, global retailers, manufacturers and distributors can benefit from more predictable and higher service levels and increased network stability. Preferred carriers have the advantage of gaining additional business opportunities from over 300 enterprise customers, representing $57B of managed freight, and more strategic, multiyear relationships.
“Markets will always have their ups and downs, and we have to stay agile and productive regardless. Real-time visibility empowers us to add more value to our customers by keeping their costs consistent and shipments predictable,” said Bartłomiej Wędzikowski of Wedzikowski Transport, a leading European truckload carrier headquartered in Poland. “We’re confident that our standing in project44’s Preferred Carriers list will send a direct signal to our customers that we are committed to their business success.”
project44 Preferred Carriers include 9 LTL carriers in North America and 320 truckload carriers, including Top200 in Europe, Top100 in North America, and Top20 in Latin America. Each of these 329 carriers demonstrated best in class performance levels and exceeded their customers’ expectations for real-time visibility.
Those included on the list are awarded with the tracking compliance badge representing that a particular carrier has met project44’s rigorous tracking standards, including high tracking percentages across multiple loads, consistent delivery of high-fidelity data, and commitment to real-time shipment visibility. Some of the pioneering carriers reaching Preferred status in May include Saia and Averitt Express on the LTL list and DSV and CR England on the truckload list.
“project44 enables LTL carriers to eliminate manual processes and increase efficiency,” said Marek Bella, leader of Europe Carrier Operations at project44. “Our data shows that truckload carriers visible on the project44 network are four times more likely to win freight and new customers.”
“We’re very proud to be recognized as a project44 Preferred Carrier. Capacity is tight, and trucking conditions have been changed dramatically and rapidly,” said Wendi Fitzsimmons, Project and IT Manager at Volpe Dedicated, a North American carrier with nearly 100 years of truckload experience. “With a streamlined data sharing process, we were able to provide a competitive customer experience by balancing pricing and on-time delivery. As a result, we’re equipped to bypass transactional interactions and invest our resources in building long-term strategic partnerships with our customers.”
“Our customer’s experience is central to our roadmap and DNA,” said Tommy Barnes, Head of Global Network Partnerships at project44. “By introducing the first global Preferred Carriers program, we want to help the entire transportation ecosystem drive more operational efficiencies and delivery excellence within the entire supply chain.”
To usher in a new era of trust and predictability, project44 has built the most expansive multimodal network, five times larger than any other visibility provider. With the recent launch of the industry’s first and only unified multimodal visibility offering , frictionless collaboration and fast time to value has become a reality.
Learn more about project44 or schedule a demo today.
About project44
project44 is the world’s leading advanced visibility platform for shippers and logistics service providers. project44 connects, automates, and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional Amazon-like experience to their customers. Connected to thousands of carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Air, Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Groupage, Truckload, Rail, Intermodal, and Ocean. project44 has placed second, behind only Amazon, on FreightWaves’ 2020 Freight Tech 25, a list of the most innovative companies across the freight industry, and received the 2020 SAP® Pinnacle Award as the Cloud Partner Integration of the Year. To learn more, visit www.project44.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005018/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
